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The role of SUMOmodification in
maintenance of human induced
pluripotent stem cells was
investigated using an inhibitor of
SUMO modification. Key
markers of pluripotency were
lost after inhibitor treatment.
Employing SUMO site
proteomics, we identified 976
sites in 427 proteins. A major
network of zinc-finger
transcription factors linked to
TRIM28 was associated with
silencing of retroviral elements.
At the site level there appears to
be a preference for SUMO2
modification over SUMO1 in
acidic domains.Highlights• SUMO inhibition in human stem cells reduced pluripotency markers.• SUMO site proteomics identified 976 SUMO sites in 427 proteins.• SUMO targets functioned in gene expression, ribosome biogenesis, and RNA splicing.• There is a preference for SUMO2 over SUMO1 modification in acidic domains.4
y Elsevier Inc on behalf of American Society for Biochemistry and
ccess article under the CC BY license (http://creativecommons.org/
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RESEARCHIdentification of SUMO Targets Associated With
the Pluripotent State in Human Stem Cells
Barbara Mojsa1 , Michael H. Tatham1, Lindsay Davidson2, Magda Liczmanska1,
Emma Branigan1, and Ronald T. Hay1,*To investigate the role of SUMO modification in the
maintenance of pluripotent stem cells, we used ML792, a
potent and selective inhibitor of SUMO Activating Enzyme.
Treatment of human induced pluripotent stem cells with
ML792 resulted in the loss of key pluripotency markers. To
identify putative effector proteins and establish sites of
SUMO modification, cells were engineered to stably ex-
press either SUMO1 or SUMO2 with C-terminal TGG to
KGG mutations that facilitate GlyGly-K peptide immuno-
precipitation and identification. A total of 976 SUMO sites
were identified in 427 proteins. STRING enrichment
created three networks of proteins with functions in
regulation of gene expression, ribosome biogenesis, and
RNA splicing, although the latter two categories repre-
sented only 5% of the total GGK peptide intensity. The rest
have roles in transcription and the regulation of chromatin
structure. Many of the most heavily SUMOylated proteins
form a network of zinc-finger transcription factors
centered on TRIM28 and associated with silencing of
retroviral elements. At the level of whole proteins, there
was only limited evidence for SUMO paralogue-specific
modification, although at the site level there appears to
be a preference for SUMO2 modification over SUMO1 in
acidic domains. We show that SUMO influences the
pluripotent state in hiPSCs and identify many chromatin-
associated proteins as bona fide SUMO substrates in
human induced pluripotent stem cells.
Pluripotent cells display the property of self-renewal and
have the capacity to generate all of the different cells required
for the development of the adult organism. The pluripotent
state is defined by a specific gene expression program driven
by expression of the core transcription factors OCT4, SOX2,
and NANOG that sustain their own expression by virtue of a
positive, linked autoregulatory loop, while activating genes
required to maintain the pluripotent state and repressing
expression of the transcription factors for lineage-specific
differentiation (1). Once terminally differentiated, somatic cell
states are remarkably stable; however, forced expression of
key pluripotency transcription factors that are highlyFrom the 1Division of Gene Regulation and Expression and 2Division of C
Dundee, Dundee, UK
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SOX2, and NANOG, leads to reprogramming back to the
pluripotent state (2–4). Under normal circumstances, the effi-
ciency of reprogramming is very low, and it is clear that there
are roadblocks to reprogramming designed to safeguard cell
fates (5, 6). The Small Ubiquitin-like Modifier (SUMO) has
emerged as one such roadblock and reduced SUMO
expression decreases the time taken and increases the effi-
ciency of reprogramming in mouse cells (7–9). Three SUMO
paralogues, known as SUMO1, SUMO2, and SUMO3, are
expressed in vertebrates. Based on almost indistinguishable
functional and structural features SUMO2 and SUMO3 are
collectively termed SUMO2/3 and share about 50% amino
acid sequence identity with SUMO1. SUMO proteomics
studies have revealed very high numbers of cellular SUMO
substrates (see (10) for a review) and as a consequence,
SUMO can influence a wide range of biological processes.
However, the proportion of the total cellular pool of a protein
that is SUMOylated varies greatly. There are rare examples of
almost constitutively SUMOylated proteins such as the Ran
GTPase RanGAP1 (11), although the majority of substrates
have such low modification stoichiometry that identification
from purified SUMO conjugates using Immunoblotting is close
to the detection limit (for review see (12)). Conjugation of
SUMO to protein substrates is mechanistically similar to that
of ubiquitin conjugation but is carried out by a completely
separate enzymatic pathway. SUMOs are initially translated as
inactive precursors that require a precise proteolytic cleavage,
carried out by a set of SUMO-specific proteases (SENPs), to
expose the terminal carboxyl group of a Gly-Gly sequence
that ultimately forms an isopeptide bond with the ε−amino
group of a lysine residue in the modified protein. The hetero-
dimeric E1 SUMO Activating Enzyme (SAE1/SAE2) uses ATP
to adenylate the C-terminus of SUMO, before forming a
thioester with a cysteine residue in a second active site of the
enzyme and releasing AMP. SUMO then undergoes a trans-
esterification reaction on to a cysteine residue in the only E2
SUMO conjugating enzyme Ubc9. Assisted by a small groupell and Developmental Biology, School of Life Sciences, University of
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SUMO Targets in Human Induced Pluripotent Stem Cellsof E3 SUMO ligases, including the PIAS proteins, RanBP2,
and ZNF451, the SUMO is transferred directly from Ubc9 onto
target proteins (13). Modification of target proteins may be
short-lived, with SUMO being removed by a group of SENPs.
Together this creates a highly dynamic SUMO cycle where the
net SUMOmodification status of proteins is determined by the
rates of SUMO conjugation and deconjugation (12). Preferred
sites of SUMO modification conform to the consensus ψKxE,
where ψ represents a large hydrophobic residue (14, 15). A
conjugation consensus is present in the N-terminal sequence
of SUMO2 and SUMO3 and thus permits self-modification
and the formation of SUMO2/3 chains (16). As a strict
consensus is absent from SUMO1, it does not form chains as
readily as SUMO2/3 (12). Once linked to target proteins,
SUMO allows the formation of new protein–protein in-
teractions as the modification can be recognized by proteins
containing a short stretch of hydrophobic amino acids termed
a SUMO interaction motif (17).
Stem cell lines are an excellent model to study the mech-
anisms that control self-renewal and pluripotency. Mouse
ESCs have been widely used for these studies as the cells can
also be used in mice for in vivo applications. However, they
display different characteristics from human ESCs. Mouse
ESCs require leukemia inhibitory factor (LIF) and bone
morphogenetic protein (BMP) signaling to maintain their self-
renewal and pluripotency (18, 19). In contrast, LIF does not
support self-renewal and BMPs induce differentiation in hu-
man ESCs (20–22). The maintenance of the pluripotent state
of hESCs requires basic fibroblast growth factor (bFGF, FGF2)
and activin/nodal/TGF-β signaling along with inhibition of BMP
signaling (23, 24). These differences may reflect the particular
developmental stages at which ESC lines are established
in vitro from mouse and human blastocysts or may be due to
differences in early embryonic development (25). As hESCs
are derived from embryos, their use is limited, but human
induced pluripotent stem cells (hiPSC) can be derived by
reprogramming normal somatic cells and display most of the
characteristics of hESCs (2) and are now widely used to study
self-renewal and pluripotency in humans.
To determine the role of SUMO modification in hiPSCs, we
made use of ML792, a highly potent and selective inhibitor of
the SUMO Activating Enzyme (26). Treatment of hiPSCs with
this inhibitor rapidly blocks SUMO modification allowing
endogenous SUMO proteases to strip SUMO from targets.
When used over the course of 48 h, hiPSCs treated with
ML792 lose the majority of SUMO conjugation but show no
large-scale changes to the cellular proteome nor loss of
viability, although markers of pluripotency are reduced.
Decreased expression of selected pluripotency markers
seems to be a consequence of SUMO removal from key tar-
gets rather than extensive changes to the proteome. SUMO
site proteomic analysis of hiPSCs reveals extensive SUMO
modification of proteins involved in transcriptional repression,
RNA splicing, and ribosome biogenesis. At the protein level2 Mol Cell Proteomics (2021) 20 100164most proteins do not appear to display SUMO paralogue-
specific modification, while at the site level there is clear
evidence of SUMO paralogue specificity. This site-specific
selectivity appears, at least in part, to be influenced by prox-
imal amino acids, with generally acidic domains being pref-
erentially modified by SUMO2.EXPERIMENTAL PROCEDURES
Antibodies and Inhibitors
Rabbit antibodies against TRIM28 (4124S, 4123S), CTCF (3418S),
OCT4A (2890S), SOX2 (23064S), NANOG (3580S), KLF4 (12173S),
SUMO2 (4971S), and mouse antibodies against TRA-1-60 (4746T),
TRA-1-81(4745T), SSEA-4 (4755T), and SMA (D4K9N) were from Cell
Signalling Technology. Anti-SALL4 (ab29112), anti-TRIM24 (ab70560),
anti-NOP58 (ab155556), anti-NESTIN (ab196908) were from Abcam.
Mouse antibody against α-Tubulin was from Bethyl Laboratories,
mouse anti-LaminA/C antibody was from Sigma Aldrich
(SAB4200236), rabbit anti-mCherry (PA5-34974), rabbit anti-TRIM33
(PA5-82152) were from Invitrogen, and mouse anti-HIS (34650) was
from Qiagen. Rabbit anti-CYTOKERATIN17 was a gift from R. Hick-
erson (University of Dundee). Sheep antibodies against SUMO1,
SUMO2 (27) were generated in-house. Secondary antibodies conju-
gated with HRP and Alexa fluorophores, Cy3 Cellmask (C10045),
Rhodamine Phalloidin (R415) were from Sigma and Invitrogen,
respectively. ML792 (1644342-14-2), MG132 (474787), and N-ethyl-
maleimide (E3876) were from Sigma Aldrich. Protease Inhibitor
cocktail (11836170001) was from Roche. Propidium iodide (P3566)
and DAPI (D1306) were from Life Technologies.
Cloning
SUMO1-KGG-mCherry and SUMO2-KGG-mCherry PiggyBac
expression vectors were generated by GATEWAY cloning. Briefly,
SUMO1, SUMO2, and mCherry fragments were PCR amplified using
the following resources: 6His SUMO1 T95K (300 nt) from pSCAI88 and
6His SUMO2 T90K (300 nt) from pSCAI89 with a common forwards
primer (5′-CACCatgcatcatcatcatcatcatgct-3′) and set of specific
mCherry fusing primers (5′-TCACCATACCCCCCTTTTGTTCCTG-3′
and 5′-TCACCATACCTCCCTTCTGCTGCT-3′); mCherry from pRHAI4
CMV-OsTIR1-mCherry2-PURO (700 nt) with a set of common
overlapping oligos (5′-GGTATGGTGAGCAAGGGCG-3′ and 5′-TTAT
TACTTGTACAGCTCGTCCATG-3′). Subsequently, PCR fragments
were fused together using overlap extension PCR, TOPO cloned into
pENTR/D-TOPO (Invitrogen) and verified by DNA sequencing. The
assembled SUMO1-KGG-mCherry and SUMO2-KGG-mCherry se-
quences were then subcloned from the pENTR vector into the
destination PiggyBac GATEWAY expression vector paPX1 (gift from
A. Dady (University of Dundee)) using LR clonase (Thermo Fisher
Scientific).
Human Induced Pluripotent Stem Cells (hiPSCs) Culture, Viability,
and Transfection Protocols
Human ESC lines (SA121 and SA181) were obtained from Cellartis/
Takara Bio Europe. All work with hESCs was approved by the UK
Stem cell bank steering committee (Approval reference: SCSC17-14).
Human iPSC lines were obtained from Cellartis/Takara Bio Europe
(ChiPS4) or the HipSci consortium (bubh3, oaqd3, ueah1, and wibj2).
Cell lines were maintained in TESR medium (28) containing FGF2
(Peprotech, 30 ng/ml) and noggin (Peprotech, 10 ng/ml) on growth
factor reduced geltrex basement membrane extract (Life Technolo-
gies, 10 μg/cm2) coated dishes at 37 ◦C in a humidified atmosphere of
SUMO Targets in Human Induced Pluripotent Stem Cells5% CO2 in air. Cells were routinely passaged twice a week as single
cells using TrypLE select (Life Technologies) and replated in TESR
medium that was further supplemented with the Rho kinase inhibitor
Y27632 (Tocris, 10 μM). Twenty-four hours after replating, Y27632
was removed from the culture medium. To make SUMO1-KGG-
mCherry and SUMO2-KGG-mCherry expressing stable cell lines,
ChiPS4 cells were transfected using a Neon electroporation system
(Thermo Fisher Scientific) with 10 μl tips. Briefly, ChiPS4 cells were
dispersed to single cells as described above, then 1 × 106 cells were
collected by centrifugation at 300g for 2 min and resuspended in 11 μl
of electroporation buffer R containing 1 μg of either paPX1-SUMO1-
KGG-mCherry or paPX1-SUMO2-KGG-mCherry PiggyBac expres-
sion vectors along with 0.2 μg of Super PiggyBac transposase
(System Biosciences). Electroporation was performed at 1150 V, 1
pulse, 30 ms, and cells plated in mTESR containing Y27632. Five days
after electroporation, mCherry positive cells were positively selected
by fluorescence-activated cell sorting (FACS) using an SH800 cell
sorter (Sony). Monoclonal cell lines were prepared from the bulk sor-
ted population by plating at low density on geltrex-coated dishes and
individual clones picked using 3.2 mm cloning discs (Sigma Aldrich)
soaked in TrypLE select. Cell lines were then expanded and analyzed
to check for expression of mCherry and His-SUMO1/2. Cell viability
following ML792 treatment was analyzed using Alamar Blue HS
reagent (Invitrogen) according to manufacturer’s instruction.
Flow Cytometry for Cell Cycle Assessment and Pluripotency
Markers
For cell cycle analysis and staining for pluripotency markers,
ChiPS4 cells were harvested using standard procedures, washed and
fixed with ice cold 70% ethanol or 4% PFA for the analysis of cell
cycle or NANOG staining, respectively. Next cells were stained with
propidium iodide or anti-NANOG primary antibody, followed by Alexa
488-conjugated secondary antibody and analyzed by flow cytometry
using a Canto analyzer (Becton Dickson). Data was then analyzed
using FlowJo 10.
Immunofluorescence, Cell Painting Assay, and High Content
Microscopy
For IF assays, ChiPS4 cells were seeded on μ-Slide 8-well (Ibidi) or
96-well plates suitable for High Content Microscopy (Nunc). Standard
IF procedure was used where appropriate. Briefly, following treat-
ments, cells were washed with PBS, fixed with 4% formaldehyde,
blocked in 5% BSA in PBS-T, and incubated with primary followed by
Alexa-conjugated secondary antibodies. Cell Painting was performed
as described by Bray et al. (29). Imaging and subsequent analysis
were performed using IN Cell Analyzer systems (GE Healthcare) and
Spotfire (Tibco). Main measures extracted from the Cell Painting assay
data set are: area of nuclei (μm2) calculated as a number of pixels in
nucleus, multiplied by the area per pixel; nuclei form factor calculated
as 4*π*Area/Perimeter2 is a measure of circularity (values between
0 and 1 for a perfectly circular object); nuclei: FITC texture correlation
is a measure of relative roughness of the image within the nucleus
correlating to the nucleolar staining.
Protein Sample Preparation and Western Blotting (WB)
ChiPS4 was maintained in a stable culture as described before and
treated with inhibitors for a stated time and dose, usually 400 nM
ML792 was used for 24 h or 48 h. For WB, cells were washed with
PBS +/+ and directly lysed in an appropriate volume of 2× Laemmli
buffer (approximately 200 μl of buffer was used per 0.5 × 106 cells)
(LD; [4% SDS; 20% Glycerol; 120 mM 1 M Tris-Cl (pH 6.8); 0.02% w/v
bromophenol blue]) and subsequently sonicated using Bioruptor Twin
(Diagenode). Protein content was assessed using BCA Protein Assay(Thermo Fisher Scientific) and for most purposes 15 μg of total protein
was loaded per lane on SDS-Page gel (NuPage 4–12% poly-
acrylamide, Bis-Tris with MOPS buffer). Proteins were transferred to
PVDF membrane using iBlot 2 Gel Transfer Device (Invitrogen).
Membranes were blocked for 1 h in 5% milk in TBS-T and incubated
overnight with primary antibodies and 1 h with secondary HRP-
conjugated antibodies before being developed using enhanced
chemiluminescence (Thermo Fisher Scientific) and exposed to film.
NiNTA Purification
Cells were washed with PBS and scraped in PBS containing
1 mM N-ethylmaleimide. The cells were then collected by centrifu-
gation at 300g for 5 min and the pellets weighed. An aliquot of the cells
was lysed in 1.2× NuPage sample buffer (Thermo Fisher Scientific) for
analysis by Western blotting. The remaining cell pellets (approximately
2 g) were lysed with 5× the pellet weight of lysis buffer (6 M guanidine-
HCl, 100 mM sodium phosphate buffer (pH 8.0), 10 mM Tris-HCl (pH
8.0), 10 mM imidazole, and 5 mM 2-mercaptoethanol). DNA was
sheared by sonication using a probe sonicator (3 min, 35% amplitude,
20 s pulses, 20 s intervals on ice, and the samples centrifuged at
4000 rpm for 15 min at 4 ◦C to remove insoluble material). The protein
concentration of the lysate was determined using BCA assay, and
6.5 mg of total protein from each sample was then incubated over-
night at 4 ◦C with 50 μl of packed pre-equilibrated Ni-NTA agarose
beads. After the overnight incubation, the supernatant was removed
and the beads were washed once with ten resin volumes of lysis
buffer, followed by one wash with ten resin volumes of 8 M urea,
100 mM sodium phosphate buffer (pH 8.0), 10 mM Tris-HCl (pH 8.0),
10 mM imidazole, and 5 mM 2-mercaptoethanol, and then six washes
with ten resin volumes of 8 M urea, 100 mM sodium phosphate buffer
(pH 6.3), 10 mM Tris-HCl (pH 8.0), 10 mM imidazole, and 5 mM
2-mercaptoethanol. Proteins were eluted from Ni-NTA agarose beads
with 125 μl 1.2× NuPAGE sample buffer for SDS-PAGE.
Mass-spectrometry-based Proteomics and Quantitative Data
Analysis
Three proteomic experiments are described in this study;
(1) Changes in total proteome of ChiPS4 cells during ML792
treatment
ChiPS4 cells were either DMSO treated (0 h condition) or treated
with 400 nM ML792 for 24 h or 48 h. Four replicates of each condition
were prepared. Crude cell extracts were made to a protein concen-
tration of between 1 and 2 mg/ml by addition of 1.2× NuPAGE sample
buffer to PBS washed cells followed by sonication. For each replicate
25 μg protein was fractionated by SDS-PAGE (NuPage 10% poly-
acrylamide, Bis-Tris with MOPS buffer—Invitrogen) and stained with
Coomassie blue. Each lane was excised into four roughly equally sized
slices and peptides were extracted by tryptic digestion (30) including
alkylation with chloroacetamide. Peptides were resuspended in 35 μl
0.1% TFA 0.5% acetic acid, and 10 μl of each analyzed by LC-MS/
MS. This was performed using a Q Exactive mass spectrometer
(Thermo Fisher Scientific) coupled to an EASY-nLC 1000 liquid
chromatography system (Thermo Fisher Scientific), using an EASY-
Spray ion source (Thermo Fisher Scientific) running a 75 μm ×
500 mm EASY-Spray column at 45 ◦C. A 240 min elution gradient with
a top ten data-dependent method was applied. Full scan spectra (m/z
300–1800) were acquired with resolution R = 70,000 at m/z 200 (after
accumulation to a target value of 1,000,000 ions with maximum
injection time of 20 ms). The ten most intense ions were fragmented by
HCD and measured with a resolution of R = 17,500 at m/z 200 (target
value of 500,000 ions and maximum injection time of 60 ms) and in-
tensity threshold of 2.1 × 104. Peptide match was set to “preferred,” a
40 s dynamic exclusion list was applied, and ions were ignored if they
had unassigned charge state 1, 8, or >8. Data analysis usedMol Cell Proteomics (2021) 20 100164 3
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engine (32). Default settings were used except the match between
runs option was enabled, which matched identified peaks among
slices from the same position in the gel as well as one slice higher or
lower. The uniport human proteome database (9606–Homo sapiens–
downloaded 24/02/2015 - 73920 entries) digested with Trypsin/P (up
to three missed cleavages, C-terminal to K and R but not before P)
was used as search space. Carbamidomethyl (C) was a fixed modi-
fication and variable modifications of Oxidation (M), Acetylation
(Protein N-term), GlyGly (K), and Phospho (ST) were also included.
Peptide mass tolerances were 20 ppm and 4.5 ppm for first and
second searches. 1% false discovery rate filtering was applied at both
peptide and protein levels. No minimum Andromeda score was
required for unmodified peptides, but a score of 40 was required for
modifications. LFQ intensities were required for each slice but LFQ
normalization was switched off. Manual LFQ normalization was done
by calculating the relative LFQ intensity compared with average LFQ
intensity for each protein found in the same slice across all 12 sam-
ples. For each peptide sample, this gave a list of sample LFQ/average
LFQ values from which the median was used to normalize all protein
LFQ intensities in that sample. The final protein LFQ intensity per lane
(and therefore protein sample) was calculated by the sum of normal-
ized LFQ values for that protein intensity in all four slices. Downstream
data processing used Perseus v1.6.1.1 (33). Proteins were only carried
forward if an LFQ intensity was reported in all four replicates of at least
one condition. Zero intensity values were replaced from log2-
transformed data (default settings) and outliers were defined by 5%
FDR from Student’s t test using an S0 value of 0.1. A summary of
these data can be found in supplemental File S1.
(2) Characterization of ChiPS4 cells stably expressing 6His-
SUMO1-KGG-mCherry and 6His-SUMO2-KGG-mCherry.
Crude cell extracts were prepared in triplicate from parental ChiPS4
cells, ChiPS4-6His-SUMO1-KGG-mCherry, and ChiPS4-SUMO2-
KGG-mCherry types and fractionated by SDS-PAGE as described
above. Samples were prepared and analyzed almost identically to the
first proteomics experiment above; gels were sectioned into four slices
per lane, tryptic peptides prepared, peptides analyzed by LC-MS/MS,
and the resultant raw data processed by MaxQuant. Deviations from
the first proteomics experiment were the omission of GlyGly (K) and
Phospo (ST) modifications, only up to two missed cleavages were
considered, and the inclusion of a second sequence database con-



















Two MaxQuant runs were performed; the first aggregating all slices
per lane into a single output (“by lane”), and the second considering
each slice separately (“by slice”). The former was used to determine
cell-specific changes in protein abundance from the proteinGroups.txt4 Mol Cell Proteomics (2021) 20 100164file, and the latter used the peptides.txt file to monitor differences in
abundance of SUMO-specific peptides between samples, to infer
overexpression levels. For the whole cell protein abundance analysis,
only proteins with data in all three replicates of at least one condition
were carried forward. In Perseus, zero intensity values were replaced
from log2-transformed data (default settings) and outliers were
defined by 5% FDR from Student’s t test using an S0 value of 0.1. A
summary of these data can be found in supplemental File S2.
(3) Identification of SUMO1 and SUMO2 modified proteins from
ChiPS4 cells.
Two repeats of this experiment were performed using approxi-
mately 0.5 × 108 cells of ChiPS4-6HisSUMO1-KGG-mCherry and
ChiPS4-6HisSUMO2-KGG-mCherry per replicate. Protein or peptide
samples were taken at different steps of the protocol to assess
different fractions. These were: whole cell extracts (WCE), NiNTA
column elutions (6His), and GlyGly-K immunoprecipitations (GGK).
The last being the source of SUMO-substrate branched peptides. The
whole procedure was carried out as described previously (34). In brief,
crude cell lysates were prepared of which approximately 100 μg was
retained for whole proteome analysis as described for the two pro-
teomics experiments above. The remaining lysate (~20 mg protein)
was used for NiNTA chromatographic enrichment of 6His-SUMO
conjugates. Elutions from the NiNTA columns were digested
consecutively with LysC then GluC, of which 7% of each was retained
for proteomic analysis (6His-SUMO fractions) and the remainder for
GlyGly-K immunoprecipitation. The final enriched fractions of LysC
and LysC/GluC GG-K peptides were resuspended in a volume of 20 μl
for mass spectrometry analysis. Peptides from whole cell extracts
were analyzed once by LC-MS/MS using the same system and set-
tings as described for the above experiments except a 180 min
gradient was used with a top 12 data-dependent method. NiNTA
elution peptides were analyzed identically except a top ten data-
dependent method was employed and maximum MS/MS fill time
was increased to 120 ms. GG-K immunoprecipitated peptides were
analyzed twice. Firstly, 4 μl was fractionated over a 90 min gradient
and analyzed using a top five data-dependent method with a
maximum MS/MS fill time of 200 ms. Secondly, 11 μl of sample was
fractionated over a 150 min gradient and analyzed using a top three
method with a maximum MS/MS injection time of 500 ms. Data from
WCE and NiNTA elutions were processed together in MaxQuant using
Trypsin/P enzyme specificity (two missed cleavages) for WCE samples
and LysC (cleaving C-terminal to K and R) with two missed cleavages,
or LysC+GluC_D/E (considering cleavage after D or E) with six missed
cleavages) for NiNTA elutions. In addition to Oxidation (M) and Acetyl
(Protein N-term), phospho (ST) modification was selected for peptides
derived from whole cell extract and 6His-SUMO2 fractions. For GGK
peptides, the additional PTM of GG-K was included in searches. LysC
enzyme was selected with three missed cleavages, or LysC+GluC_D/
E allowing eight missed cleavages. The human database and se-
quences of the two exogenous 6His-SUMO-KGG-mCherry constructs
described above were used as search space. In all cases every raw file
was treated as a separate “experiment” in the design template such
that protein or peptide intensities in each sample were reported,
allowing for manual normalization where appropriate. Matching be-
tween runs was allowed but only for peptide samples from the same
cellular fraction (WCE, 6His or GGK), the same or adjacent gel slice
(WCE), the same protease (6His and GGK), and the same LC elution
gradient. For example, spectra from adjacent gel slices in the WCE
fraction across all lanes were matched, and spectra from all GG-K IPs
that were digested by the same enzymes were matched. Normaliza-
tion followed a similar method as described above where “equivalent”
peptide samples (i.e., those from the same gel slice or “equivalent”
peptide samples) from different replicates were compared with one
another. For each protein or peptide common to all equivalent peptide
SUMO Targets in Human Induced Pluripotent Stem Cellssamples, the intensity in that sample relative to the average across all
equivalent samples was calculated. The median of that relative in-
tensity in each peptide sample was used to normalize all protein or
peptide intensities from that sample. The final total protein or peptide
intensity per replicate was calculated by the sum of all normalized
intensities in samples derived from that replicate. It is important to
note that peptide samples derived from SUMO1 and SUMO2 cells
were considered equivalent for normalization purposes, which as-
sumes largely similar abundances of proteins or peptides between cell
types. Zero intensity values were replaced from log2-transformed data
(Perseus default settings) and outliers were defined by 5% FDR from
Student’s t test using an S0 value of 0.1. A summary of these data can
be found in supplemental File S3.
Bioinformatic Analysis of the SUMO Site Proteomics
In total, 429 proteins identified with at least one SUMO1 or SUMO2
modification site were uploaded to STRING (35) for network analysis.
Only proteins associated by a minimum STRING interaction score of
0.7 (high confidence) were included in the final network. Disconnected
nodes were removed. Selected groups of functionally related proteins
were resubmitted to STRING create smaller subnetworks. These were
visualized in Cytoscape v 3.7.2 (36) allowing the graphical display of
numbers of sites identified and total GG-K peptide intensity into the
protein networks. Net charge at pH 7.4 of sequences surrounding
SUMO conjugation sites was predicted using 21 residue sequence
windows input into the isoelectric point calculator tool (37). Profiles of
charge distribution along full-length protein sequences were calcu-
lated on a sequence window basis for each amino acid. The net
charge for sequence windows varying from 5 to 100 amino acids
around each amino acid was calculated assuming a score of −1 for
aspartic acid or glutamic acid residues and +1 for lysine or arginine.
Consideration of histidine residues had little effect on overall profiles.
For each amino acid, the 20 different net charge per window values
were all plotted on the same charts as line graphs using amino acid
residue number as the x-axis value and net window charge on the y-
axis.
RNA Preparation and Real-time Quantitative PCR (RT-qPCR)
Total RNA was extracted using RNeasy Mini Kit (Qiagen) and treated
with the on-column RNase-Free DNase Set (Qiagen) according to the
manufacturer’s instructions. RNA concentration was then measured
using NanoDrop and 1 μg of total RNA per sample was subsequently
used to perform a two-step reverse transcription polymerase chain
reaction (RT-PCR) using random hexamers and First Strand cDNA
Synthesis Kit (Thermo Fisher Scientific). Each qPCR reaction contained
PerfeCTa SYBR Green FastMix ROX (Quantabio), forward and reverse
primer mix (200 nM final concentration) and 6 ng of analyzed cDNA and
was set up in triplicates in MicroAmp Fast Optical 96-Well or 384-Well
Reaction Plates with Barcodes (Applied Biosystems). The sequences
of primers used were as follows: NANOG (hNANOG_FOR624
ACAGGTGAAGACCTGGTTCC; hNANOG_REV722 GAGGCCTT
CTGCGTCACA), SOX2 (hSOX2 _FOR907 TGGACAGTTACGCGCA
CAT; hSOX2_REV1121 CGAGTAGGACATGCTGTAGGT), OCT4A
(hOCT4A_FOR825 CCCACACTGCAGCAGATCA and hOCT4A_
REV1064 ACCACACTCGGACCACATCC), KLF4 (hKLF4_FOR1630
GGGCCCAATTACCCATCCTT and hKLF4_REV1706 GGCATGA
GCTCTTGGTAATGG), TBP (hTBP_FOR896 TGTGCTCACCCACCAA
CAAT; hTBP_REV1013 TGCTCTGACTTTAGCACCTGTT). Data were
collected using QuantStudio 6 Flex Real-Time PCR Instrument and
analyzed using corresponding software (Applied Biosystems). Relative
amounts of specifically amplified cDNA were calculated using TBP
amplicons as normalizers.Experimental Design and Statistical Rationale
All proteomics analyses used a label-free quantitation method
employing either triplicate or quadruplicate cell cultures (biological
replicates). Biological replicates were individual cell cultures grown
and treated separately from one another but originally derived from a
single cell line culture just prior to the experiment. For example,
comparisons between different cell lines took individual large-scale
cultures for each cell line and split the cells equally among repli-
cate culture dishes. Once these had grown to appropriate levels of
confluence, they were treated as described. Intensity data from
multiple mass spectrometry runs of the same peptide sample
(technical replicates) were normalized against other samples from
the same mass spectrometry run and then quantitative data from
identical peptide samples aggregated together by summation prior
to statistical analyses. Protein or peptide outliers were determined
by two-sample Student’s t-tests in pairwise comparisons. Specific
FDR and S0 values for filtering are described for each experiment
above.
RESULTS
Inhibition of SUMO Modification Leads to Decreased
Expression of Pluripotency Markers in hiPSCs
The pluripotent state in hESCs and hiPSCs is controlled by
a network of transcription factors and other chromatin-
associated proteins that determine the chromatin environ-
ment of key genes (1). To test the potential role of SUMO
modification in the maintenance of pluripotency in hiPSCs, we
used ML792 (26) a potent and selective inhibitor of SUMO
Activating Enzyme (SAE). This inhibitor has been reported to
block proliferation of cancer cells, particularly those over-
expressing Myc (26), but has not been evaluated in hiPSCs. To
address the role of SUMO modification in hiPSCs, ChiPS4
cells were treated with ML792 in a series of time-course and
dose–response experiments. We determined that 400 nM
ML792 was the lowest concentration that effectively reduced
SUMO modification after 4 h treatment with minimal effects on
cell viability (supplemental Fig. S1). We restricted our analyses
to ML792 treatment times that did not exceed 48 h, such that
the early effects of SUMO modification inhibition could be
evaluated. Microscopic examination revealed that ML792
treatment caused morphological changes with the ChiPS4
cells becoming larger and flatter (Fig. 1A, supplemental
Fig. S2, A–C). The rate of proliferation was unchanged after
24 h but was slightly reduced after 48 h (Fig. 1B). DNA staining
of the cells and analysis by flow cytometry indicated that the
cell cycle distribution after 24 h was unaltered by ML792
treatment but after 48 h displayed an increased proportion of
cells in G2 phase and cells with increased DNA content sug-
gesting endoreplication or failed mitosis (Fig. 1C). Western
blot analysis revealed a loss of high-molecular-weight SUMO1
and SUMO2 conjugates and concomitant increase in free
SUMOs in ChiPS4 cells (Fig. 1D). This is likely to be a
consequence of the rapid removal of SUMO from modified
proteins by SUMO-specific proteases (SENPs), which can be
also measured by calculating a nuclear/cytoplasmic ratio forMol Cell Proteomics (2021) 20 100164 5
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FIG. 1. Inhibition of SUMO modification leads to decreased expression of pluripotency markers in ChiPS4 cells. A, ChiPS4 cells were
treated with SUMO E1 activating enzyme inhibitor ML792 (400 nM) or DMSO vehicle for the indicated time, fixed, and stained using DAPI and
Cy3 Cellmask. Cells were further analyzed using high contents microscopy (scale bar = 100 μm). B, ChIPS4 cells were seeded at a standard
density of 3 × 104 cells/cm2 in triplicate and either DMSO or 400 nMML792 treated for the indicated durations. Cells were harvested using Tryple
Select and counted. Data are plotted as a mean (line) ± SEM of individual replicates (dots), n = 3. Statistical significance was calculated with
t-tests corrected for multiple comparisons using Holm–Sidak’s method (*p < 0.05 significantly different from the corresponding DMSO control).
C, cells were collected as in (B), fixed, stained with propidium iodide (PI), and analyzed by flow cytometry. Plots are representative of three
independent experiments. D, crude cell extracts taken from cells incubated at the indicated time points with 400 nM ML792 were analyzed by
Western blotting to determine conjugation levels of SUMO1, SUMO2/3 (rabbit), and abundance of key pluripotency markers NANOG, SOX2,
KLF4, and OCT4. Anti-Actin and anti-lamin A/C western blots were used as loading controls. Asterisk (*) indicates free SUMO1 or SUMO2/3.
E, cells were treated with ML792 and after the indicated time total RNA was extracted. mRNA levels of NANOG, OCT4, SOX2, and KLF4 were
determined by quantitative PCR. Relative mRNA expression levels (normalized to TBP) were plotted as mean values ± SEM of four independent
experiments. **p < 0.01; ***p < 0.001; ****p < 0.0001 significantly different from the corresponding value for untreated control (two-way ANOVA
followed by Sidak’s multiple comparison test).
SUMO Targets in Human Induced Pluripotent Stem CellsSUMO signal in high contents microscopy (supplemental
Fig. S2E). Analysis of the protein levels of key pluripotency
markers indicated that levels of KLF4 and NANOG were
substantially reduced in response to ML792 treatment,
whereas levels of SOX2 and OCT4 displayed only a marginal
reduction (Fig. 1D, supplemental Fig. S2D). This appeared to
be predominantly a consequence of reduced transcription as
NANOG and KLF4 mRNA levels also reduce after ML792
treatment, while levels of OCT4 and SOX2 mRNA were not
significantly changed (Fig. 1E).6 Mol Cell Proteomics (2021) 20 100164Inhibition of SUMO Modification Induces Phenotypic
Changes but not Large-scale Proteomic Changes in hiPSC
To further investigate the nature and causes of the observed
morphological changes induced by the inhibition of SUMO
modification, ChiPS4 cells were treated with ML792 for 48 h
and analyzed by phenotypic screening using a cell painting
assay (29) (Fig. 2A). Principle component analysis (PCA) indi-
cated that there are clear differences between cells treated
with ML792 for 48 h and untreated or vehicle (DMSO)-treated
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FIG. 2. Inhibition of SUMOmodification causes morphological changes but does not trigger large-scale proteome changes in hiPSCs.
A, cell painting analysis. ChIPS4 cells were treated with PBS, DMSO vehicle, or 400 nM ML792 for 48 h. Cells were then stained, fixed, and
analyzed using high content microscopy. The experiment was performed three times with eight replicates per condition. Feature information
extracted from Cell Painting analysis was focused on subcellular compartments most affected by ML792 treatment. Most variation between
treatments and controls in principal component analysis was captured by PC1. Selected graphs represent quantitation of individual measures
contributing to the difference observed in principal component analysis: area of nuclei; nuclei form factor (size and shape of nucleus); nuclei FITC
texture correlation (size of nucleolar structures). B, ChIPS4 cells were treated for 48 h with DMSO vehicle or 400 nM ML792, fixed, and stained
with DAPI (blue), anti-SUMO1 or anti-SUMO2/3 (sheep) (red) and anti-NANOG or anti-NOP58 (green) antibodies. Immunofluorescence (IF)
images were obtained using Leica SP8 confocal microscope and a 60× water lens. All images contain 25 μm scale bar. C, crude extracts from
hiPSCs treated in triplicate with ML792 for 24 h or 48 h or not (0 h) were analyzed by label-free proteomics and the change in protein abundance
of detected pluripotency markers (n = 14) was calculated as % of 0 h intensity. Paired t test p values are indicated. Average reduction is 13.2%
(24 h) and 25.7% (48 h). D, scatter plot of Log2 24 h/0 h and log2 48 h/0 h abundance change for the entire 4741 protein whole cell proteomic
dataset. Extreme outliers are indicated. All identified core and linker histones are represented by colored markers others are in gray. Linker
histones were identified by STRING analysis as a functionally related group of proteins that are significantly reduced in abundance at 48 h
compared with 0 h. Core histone proteins are indicated for reference.
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SUMO Targets in Human Induced Pluripotent Stem Cellscompartment (Fig. 2A). Feature extraction identified changes
in the global size (Area of nuclei) and shape (Nuclei form
factor) of the nucleus and the structure of the nucleolus
(Nuclei: FITC texture correlation) (Fig. 2A, supplemental
Fig. S2, C and E). These findings were validated using tradi-
tional immunofluorescence (IF) approaches (Fig. 2B,
supplemental Fig. S2, D and E). Consistent with previously
presented data, NANOG expression and the size and shape of
the nucleus are both affected by ML792 treatment. NOP58
was used as a marker of the nucleolus, which undergoes a
dramatic increase in size and shape (Fig. 2B, supplemental
Fig. S2E). As expected, the classic punctate nuclear locali-
zation pattern of SUMO1 and SUMO2 is altered by their
deconjugation from substrates, becoming more diffuse and
less tightly associated with the nucleus (Fig. 2B, supplemental
Fig. S2E).
To evaluate the effect of inhibition of SUMO modification on
the global proteome in hiPSCs, total protein extracts were
prepared from ChiPS4 cells either untreated or treated with
ML792 for 24 or 48 h and analyzed by label-free quantitative
proteomics. Data for 4741 proteins was obtained
(supplemental File S1). Consistent with SUMO conjugation
influencing the pluripotent state, known pluripotency markers
were modestly but significantly reduced during 24 h and 48 h
ML792 exposure (Fig. 2C). However, overall protein abun-
dance changes compared at both time points showed little
evidence for large-scale shifts (Fig. 2D), with few functionally
related proteins undergoing coordinated regulation according
to STRING: Linker histones appeared to be reduced in
abundance after 48 h, but not 24 h (Fig. 2D), and proteins from
the gene ontology group “Collagen-associated extracellular
matrix” had members both up- and downregulated
(supplemental File S1). Alone these data do not appear to
provide an obvious link between the morphological changes
induced by SUMO inhibition and underlying protein abun-
dance changes. Thus it is likely that the deSUMOylation of key
regulators or the accumulation of multiple small protein
abundance changes is responsible for the phenotypic con-
sequences of ML792 treatment on hiPSCs.
Generation of hiPSC Lines for SUMO Proteomic Analysis
Our data suggest that SUMO influences the pluripotent
state of hiPSCs. Given that previous studies of SUMOylation
have typically focused on somatic cells, it was important to
establish the SUMOylome of hiPSCs to identify candidate
proteins that either directly or indirectly contribute to the
observed phenotype. We adapted a proteomic approach that
allows sites in proteins modified by SUMO1 and SUMO2/3 to
be identified (38). To enable this analysis in hiPSCs, the
ChIPS4 cell line was engineered to stably express 6His-
SUMO-mCherry constructs for either SUMO1 or SUMO2
(Fig. 3, A and B) that incorporated the C-terminal TGG to KGG
mutations to facilitate GlyGly-K peptide immunoprecipitation
and identification as described previously (38). As mCherry is8 Mol Cell Proteomics (2021) 20 100164linked to the C-terminus of SUMO, the expressed fusion
protein will be processed by endogenous SUMO proteases to
expose the C-terminal GlyGly sequence for conjugation and
release free mCherry. A representative single cell clone for
each SUMO was selected based on the expression of free
mCherry and the level of SUMO paralogue expression
(Fig. 3C). Clones selected for SUMO site proteomic experi-
ments were extensively characterized to ensure that the
exogenous SUMO was functional and that the cells retained
their pluripotency. Western blotting indicated that His-tagged
SUMO-KGG paralogues were conjugated to substrates in
response to heat shock (supplemental Fig. S3). Cells
expressing SUMO1-KGG and SUMO2-KGG had normal cell
cycle profiles (supplemental Fig. S4A), expressed levels of
pluripotency markers comparable to wild-type ChIPS4 cells
(supplemental Fig. S4, B and C), and retained the ability to
differentiate into endoderm, ectoderm, and mesoderm
(supplemental Fig. S4D). Analysis of the whole cell proteomes
(Fig. 3D, supplemental File S2) of ChIPS4 cells expressing
SUMO1-KGG and SUMO2-KGG identified the expected
exogenous mCherry, SUMO1, and SUMO2 peptides (Fig. 3E)
while peptides common to both endogenous and exogenous
SUMOs showed that both types were conjugated to sub-
strates at roughly similar levels (Fig. 3F). Importantly, the
engineered cell lines did not show large-scale differences from
parental cells in their expressed proteomes (Fig. 3, G and H,
supplemental File S2). Together these data indicate that
expression of SUMO mutants did not disrupt the normal
pluripotent state or differentiation potential of ChiPS4 cells.
Identification of SUMO1 and SUMO2 Targets in hiPSCs
The workflow for the identification of SUMO1 and SUMO2
targets incorporates proteomic analysis at three levels
(supplemental Fig. S5A). This involved analysis of whole cell
extracts to monitor total protein levels, analysis of nickel af-
finity purified proteins to identify SUMOmodified proteins, and
analysis of GG-K immunoprecipitations to define sites of
SUMO modification. SUMO1/SUMO2 comparisons can be
made at the site level because after LysC digestion both
mutants leave the same GG-K adduct on substrates
(supplemental Fig. S5B), and so intensity comparisons can be
used to infer preference for SUMO type at the site level. The
experiment was conducted twice in triplicate and PCA indi-
cated that replicates performed at the same time displayed a
high degree of clustering (supplemental Fig. S5C). PCA also
indicated clear differences between SUMO1 and SUMO2 as
well as between experiments carried out at different times
(supplemental Fig. S5C). This is likely to be a reflection of the
precise growth state of the cells when the experiment was
conducted. Very few total protein abundance differences be-
tween SUMO1 and SUMO2 cell were consistent to both
experimental runs, but there were substantial and consistent
differences between SUMO1 and SUMO2 at both nickel af-
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FIG. 3. ChiPS4 cell lines engineered for SUMO1 and SUMO2 site proteomic analysis. A, overview of the principles behind the SUMO-
mCherry construct design and the utility of the expressed proteins for SUMO site proteomic analysis in CHiPS4 cells. The C-terminal
mCherry protein used for cell selection is cleaved away from 6His-SUMO by endogenous SUMO proteases allowing conjugation to substrate
proteins. B, scheme representing the piggyBac construct design used for generation of ChiPS4 cell lines expressing 6His-SUMO1-KGG-
mCherry or 6His-SUMO2-KGG-mCherry. C, flow cytometry analysis of single cell clones using mCherry expression levels to infer SUMO
expression levels. D, coomassie-stained SDS-PAGE gel fractionating whole cell protein extracts from parental CHiPS4 cells (WT) and the
selected 6His-SUMO-KGG-mCherry clones prepared in triplicate. This was used to monitor SUMO overexpression levels using proteomic
analysis and each lane was excised into four sections allowing differentiation between conjugated (slices A–C) and unconjugated (Slice D)
SUMO forms. E, peptide intensity data from slices A–D for two peptides each from 6His-SUMO1-KGG (left) and 6His-SUMO2-KGG (center) that
are unique to the exogenous constructs. Data for 20 mCherry peptides are also shown (right). F, peptide intensity data from slices A–C for four
peptides from SUMO1 (left) and three from SUMO2 (right) that are common to both the endogenous and exogenous forms of the proteins. G,
quantitative data from 3863 proteins identified from the gel shown in (D) were compared by principal component analysis. H, numerical ratio and
unpaired Student’s t test results comparing WT parental cells with 6His-SUMO1-KGG-mCherry cells (left), and WT with 6His-SUMO2-KGG-
mCherry cells (right). Outliers (red markers) were defined in Perseus by 5% FDR with an S0 value of 0.1 (78 outliers from WT versus SUMO1 cells
and 64 from WT versus SUMO2 cells). Gene names from extreme outliers are indicated.
SUMO Targets in Human Induced Pluripotent Stem Cellsand E). Across the two experimental runs (supplemental
Fig. S5E) and aggregating the data for SUMO1 and SUMO2,
a total of 976 SUMO sites were identified in 427 proteins.
Approximately 84% of these had already been described in atleast one of four large-scale SUMO2 and two SUMO1 site
proteomics studies totalling 49,824 unique sites of non-stem-
cell origin (Fig. 4A, supplemental File S3). DNA methyl trans-
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FIG. 4. Functions of SUMO1 and SUMO2 targets in hiPSCs. A, in total, 976 SUMO sites were identified from 6His-SUMO1-KGG and 6His-
SUMO2-KGG IPS cells, of which 155 were novel compared with previous high-throughput SUMO site proteomics studies (supplemental File S2).
Proteins with three or more novel sites are highlighted. B, summary of the top 50 SUMO substrates by total SUMO1+SUMO2 GGK-peptide
intensity for all identified sites. Gene names are shown with numbers of sites in brackets. Bars are color-coded by category shown in panel
D. Insert shows contribution to total GGK peptide intensity of proteins from the categories shown in (D) (note categories are not mutually
exclusive). C, immunoblot analysis of ChIPS4 cells treated with the SUMO E1 conjugating enzyme inhibitor ML792 or DMSO for 48 h. Total
protein extracts were probed with anti-TRIM28, anti-TRIM24, anti-CTCF, anti-DNMT3b, anti-SALL4, anti-TRIM33, and anti-tubulin or anti-Lamin
A/C antibodies (loading controls). SUMO-modified species above the band for unmodified proteins (*) reduce with ML792 treatment. D, STRING
interaction network of the 427 IPS SUMO substrates. Only high confidence interactions were considered from “Text mining,” “Experiments,” and
“Databases” sources. Network PPI enrichment p-value <1.0 × 10−16. Nodes are colored by functional or structural group as indicated.
SUMO Targets in Human Induced Pluripotent Stem Cellstranscription factor SALL4 were among a small group of
proteins with at least three novel sites in this study (Fig. 4A).
Although peptide intensity is a relatively imprecise proxy for
abundance, it has been successfully used for SUMO-
substrate branched peptides to separate high occupancy
from low occupancy sites (39). For our data total GG-K pep-
tide intensity suggests SALL4 is among the most modified
SUMO substrate in hiPSCs and contains 17 sites of modifi-
cation (Fig. 4B). DNMT3B contains 12 sites and is also among10 Mol Cell Proteomics (2021) 20 100164the most abundantly modified substrates, while the methyl
DNA binding protein MBD1 contains eight sites and is also in
the top cohort of substrates by modified peptide intensity
(Fig. 4B). Transcription intermediary factors 1 α and 1 β
(TRIM24 and TRIM28) are also both highly modified sub-
strates. The boundary and chromatin isolation factor CTCF is
heavily modified with SUMO, consistent with a role for SUMO
in chromatin architecture (Fig. 4B). There is also evidence for
extensive SUMO chain formation as the branch points from
SUMO Targets in Human Induced Pluripotent Stem CellsSUMO2/3 chains are among the most abundant GG-K pep-
tides (Fig. 4B). Strikingly, the SUMOylated forms of a number
of these nuclear substrates could be detected directly in total
whole cell lysates from control ChiPS4 cells, but not ML792-
treated hiPSCs (Fig. 4C), implicating SUMO as a major regu-
lator of the total pool of these proteins. SUMO modification of
some of these proteins was confirmed by immunoprecipitation
using target-specific antibodies followed by western blotting
with either SUMO1 or SUMO2 antibodies (supplemental
Fig. S6). STRING enrichment analysis of the 427 modified
proteins created a network consisting of three broad clusters
that could be categorized as having functions in ribosome
biogenesis, RNA splicing, and regulation of gene expression
(Fig. 4D). Despite forming extensive protein networks
(supplemental Fig. S7, A and B), proteins involved in ribosome
biogenesis and RNA splicing represented only approximately
5% of the total GGK peptide intensity (Fig. 4B insert). Most of
the remainder have roles in transcription and chromatin
structure or are closely linked to these functions
(supplemental Fig. S7, C–H). There is a prominent network of
zinc-finger transcription factors, closely associated with
TRIM28 (supplemental Fig. S7C), which contains many of the
most heavily SUMOylated proteins identified. The TRIM-ZNF-
SUMO axis may play a key role in silencing retroviral elements,
and this may be particularly important in hiPSCs (40). Histone
proteins themselves form a small cluster of SUMO substrates
(supplemental Fig. S7D), which STRING positioned in the
center of the gene regulation region of the whole network
(Fig. 4D). The transcriptional regulators themselves form a
bipolar network (supplemental Fig. S7E) with the smaller
subcluster consisting mainly of apparently weakly modified
ribosomal proteins and the larger subcluster containing many
heavily modified chromatin associated proteins. Strikingly,
many members of chromatin remodeling complexes such as
PRC2, BAF, and NURD (supplemental Fig. S7, F–H) are
among this group. Together these networks and clusters of
proteins provide multiple direct and indirect links between
SUMO and chromatin structure regulation.
Differences between SUMO1 and SUMO2 at the Protein
and Acceptor Site Level
The proteomic experimental design allowed quantitative
comparisons between SUMO1 and SUMO2 at multiple stages
of the purification process (supplemental Fig. S5A): SUMO1/
SUMO2 ratios from crude hiPS cell extracts show there to be
few differences (0.03% significant) at the whole proteome
level (Fig. 5A). There are also surprisingly few differences
(7.8% significant) between NiNTA purifications from the two
cell types (Fig. 5A). Exceptions include the well-documented
SUMO1 substrate RanGAP1, along with TRIM24 and
TRIM33, which all appear to show similar levels of SUMO1
preference (Fig. 5A). In contrast, over half of the GGK-
containing peptides quantified in both experimental runs and
both cell lines showed large and significant differencebetween SUMO1 and SUMO2 cells (Fig. 5A). Extreme exam-
ples of SUMO1 preferential sites include not only RanGAP1
K524, but also TRIM33 K776, NFRKB K359, PNN K157, TFPT
K216, and two sites in TOP1 (K117 and K134) (Fig. 5A).
Conversely, TRIM28 contains two of the most SUMO2-
preferential sites at K507 and K779, and lysines 48 and 63
from ubiquitin also seem to be among the abundant SUMO2
acceptors (Fig. 5A). In the context of whole proteins, three key
proteins in our dataset, SALL4, TRIM24, and TRIM33, show
largely SUMO1 preferential modification, while TRIM28 and
CTCF show apparent preference for SUMO2 (Fig. 5, B and C).
This was broadly confirmed by Western blot analysis from
NiNTA purifications (Fig. 5D) and immunoprecipitation
(supplemental Fig. S6), although in some cases the degree of
preference was not as striking as expected. In particular,
TRIM24 and TRIM28, which contained some of the most
extreme SUMO paralogue-selective sites according to mass
spectrometry, appeared by Western Blot of the whole proteins
not to display strong SUMO paralogue preference. It is
possible that some sites in these proteins that significantly
influence overall modification were not detected by mass
spectrometry and so skewed predictions of protein-level
preference. It is important to note that although Western blot
analysis of NiNTA purifications confirmed the SUMO2-
preferential modification of CTCF, both the modified and un-
modified forms of CTCF were purified (Fig. 5D). Thus, it seems
likely that large amounts of unmodified CTCF obscured the
SUMO2 preference in the NiNTA purification proteomic data.
This effect may be rare, but highlights potential weaknesses in
proteomics studies when using relatively low-stringency pu-
rifications such as 6His/Ni-NTA pull-downs.
Preference for SUMO2 Modification in Regions of Higher
Negative Charge
The proteomic data reveal many multiply modified proteins
to have a strong overall SUMO paralog selection. TOP1,
TRIM33, ZNF462, and ZNF532 all contain multiple SUMO1-
specific sites, and conversely, DNMT3a, CHD4, ubiquitin,
and SUMOs 2 and 3 themselves have a majority of SUMO2-
specific sites (supplemental Fig. S8). However, a number of
substrates such as GTF2I, SAFB2, and MGA (supplemental
Fig. S8) have a mixture of sites showing varied SUMO type
preference. This broad range of site-specific SUMO paralogue
preference raises the question of how specificity is deter-
mined. By averaging the SUMO1/SUMO2 peptide intensity
ratio data over the two experimental runs, we ranked 739 sites
by paralogue preference from SUMO1 to SUMO2 (Fig. 6A).
Not all sites could be included for sequence analysis as sites
close to protein N or C termini lacked amino acids in their
sequence windows. Sequence logos of the top and bottom
123 sites (one-sixth of total) show broadly similar motifs for
SUMO1 and SUMO2 sites (Fig. 6B), with both showing the
characteristic ψKxE motif. However, outside the consensus
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FIG. 5. Validation of SUMOylation status of abundant SUMO substrates in ChIPS4 cells. A, scatter plots of log2 SUMO1/SUMO2 ratio
and −log10 Student’s t test p-value for proteins or peptides detected in the different cellular fractions. Red markers were found to be significantly
different in both experimental runs. Selected outliers are indicated. Numbers of significantly differing proteins or peptides compared with the
entire set of proteins or peptides quantified are shown. B, schematic presentations of selected proteins found to have high total GG-K peptide
intensities in the present study. Site positions are indicated by number. SUMO preference is represented by color and GGK peptide intensity by
the size of the site node (see key). Site node border line thickness represents number of experiments in which it was found to show a significant
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SUMO Targets in Human Induced Pluripotent Stem Cellsthan SUMO1 sites, and a significant number of SUMO1 sites
have P in +3 (Fig. 6B). More generally, D/E residues are more
enriched within the 21 residue sequence windows of SUMO2
than SUMO1. This is confirmed by sequence window charge
analysis (Fig. 6C), which shows that acceptor lysine residues
preferentially modified with SUMO2 over SUMO1 are more
likely to be embedded in a sequence that is net negatively
charged at pH7.4 than those showing SUMO1 preference. This
trend is also generally progressive across the spectrum of site-
specific SUMO paralogue selection (supplemental Fig. S9). For
some proteins where SUMO paralogue preference varies in
different regions of the sequence, this coincides with local
charge variations consistent with SUMO2 preference in acidic
domains. SALL4, CHD4, and SAFB (Fig. 6D) show that sites
preferentially modified by SUMO2 were generally negatively
charged while SUMO1-preferential modification took place in
regions of the protein that were more positively charged.DISCUSSION
Our studies indicate that SUMO influences the pluripotent
state of hiPSCs. Using a potent and highly specific inhibitor of
the E1 SUMO Activating Enzyme ML792 (26) we blocked de
novo SUMO modification, which allowed endogenous SUMO
specific proteases to remove SUMO from previously modified
proteins. In this way, ML792 treatment effectively deSU-
MOylated cellular proteins. In response to 48 h of 400 nM
ML792 exposure, ChIPS4 cells showed reduced level of plu-
ripotency markers and underwent dramatic morphological
changes, particularly to nuclear structure and size. Over the
same period of time, there appeared to be few large-scale
changes to the cellular proteome, implying that the conse-
quences of loss of SUMOylation in hiPSCs primarily involve
functional changes to factors critical for nuclear structure and
function, probably followed by multiple modest protein
abundance changes, which together lead to the observed
phenotype. Candidates for these SUMOylated factors were
identified by SUMO site proteomic analysis. The major
network that accounted for the bulk of SUMO modification
sites was associated with negative regulation of gene
expression. At the heart of this network is TRIM28, the histone
methyl transferase SETDB1 and the Chromobox silencer
CBX3. ChIP-seq derived locations of TRIM28, SETDB1, and
CBX3 indicate that they are associated with retroviral ele-
ments (41). These proteins along with SUMO have previously
been shown to function in HERV silencing in mouse ES cells
(40, 42) and adult human cells (43, 44) and this is consistent
with our proteomic analysis that indicates that all three ofSUMO preference. Protein nodes are labeled with the gene name and the
intensity from SUMO1 cells/total from SUMO2 cells. Edges linking site
sequence with first and last residues at the top of the protein node. C, sum
cellular fractions analyzed. § – No data acquired. D, immunoblot analysis
SUMO2 cells either treated or not with 400 nM ML792. *Position of unmthese proteins are heavily SUMO modified (Fig. 4). The
TRIM28 corepressor functions by interacting with DNA-bound
Kruppel type Zinc finger proteins, and these proteins are also
identified as being SUMO modified in our proteomic studies
and are part of the large TRIM28 centric network of SUMO
modified proteins. It is also suggested that a number of
developmental genes are repressed by TRIM28/KRAB-ZNFs
through H3K9me3 and de novo DNA methylation of their
promoter regions (45), thus making TRIM28/ZNFs a crucial link
in maintenance of pluripotency in human stem cells. These
data are consistent with the wide distribution of SUMO on
chromatin (46–49) and with a very different distribution in
murine fibroblasts and ESCs (9). Recently Theurillat et al. (50)
reported a SUMO site proteomic analysis of mouse ESCs. In
this case the method used allowed analysis of endogenous
SUMO2 but not SUMO1 modification sites. The number of
sites identified by Theurillat et al. (49) was similar (608 SUMO2
sites in 350 proteins) to that reported here (976 SUMO1 plus
SUMO2 sites in 427 proteins), as were the major functional
networks. However, the precise targets identified were very
different, with only SALL4 of the top 20 mouse ES cell specific
proteins being present in the top 50 (based on peptide in-
tensity) SUMO modified proteins in human stem cells reported
here (Fig. 4B). Such differences presumably reflect the differ-
ences between mESCs and hiPSCs and the developmental
stages that these cells represent. While the mouse cells were
established from blastocysts, the human cells are derived by
reprogramming normal somatic cells (25). In our study the
analysis of SUMO1 and SUMO2 proteomes was facilitated by
expression of exogenous versions of modified SUMOs. While
expression levels of the exogenous SUMO were maintained at
levels close to endogenous SUMO1 and SUMO2/3, this is by
definition overexpression, and it is possible that this over-
expression could influence the extent to which substrates and
modification sites are conjugated to the different SUMO
paralogues.
Analysis of theSUMOproteomeof theChIPS4hiPSCsshows
that well-defined groups of proteins are modified. Aside from
the TRIM28/ZNF network mentioned above, proteins involved
in “ribosome biogenesis” and “splicing” are SUMO modified,
and this likely impacts on the normal growth and self-renewal of
the hiPSCs. However, the largest network of proteins falls into
the category of “negative regulation of transcription,”withmany
chromatin remodelers, chromatin modification, and DNA
modification enzymes identified as SUMO substrates. Thus,
SUMO modification is likely to play an important role in the
control of pluripotency in hiPSCs by repressing genes that
either disrupt pluripotency or drive differentiation.color is based on SUMO preference calculated by total GGK peptide
s to proteins are angled relative to their position in the linear protein
mary of log2 SUMO1/SUMO2 intensity measured in each of the three
of whole cell extracts (input) and NiNTA purifications from SUMO1 and
odified protein in NiNTA purifications.
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FIG. 6. SUMO paralogue preference at the site level in hiPSCs is influenced by proximal acidic residues. A, Log2 SUMO1/SUMO2 ratio
versus rank of ratio for 738 GG-K containing peptides that could be numerically compared between SUMO1 and SUMO2 samples. Top and
bottom 1/6th (123 sites) by ratio are selected to represent SUMO paralogue-preferential sites (colored) with the remainder marked in gray. B,
pLogos (54) for the 123 SUMO1 or SUMO2 specific sites as shown in part (C) using the human proteome as background. Two analyses were
performed using the entire 21 residue window (left), and the 17 residue window of the same sequences without the 4 residue SUMO consensus
motif (right). The position of the consensus sequence region is boxed with a dashed line (left) or shown by a dotted line (right). C, comparison
between SUMO1 and SUMO2-preferential sites for predicted net charge at pH7.4 of the amino acid region encompassing −10 to +10 residues
around the acceptor lysine. Charge predicted using Isoelectric Point Calculator tool (37). D, schematic presentations summarizing site-specific
SUMOylation data, and predicted sequence charge distribution for SALL4, CHD4, and SAFB2. Net charge at each amino acid position in the
sequence (left) was calculated for sequence windows of sizes from 5 to 100 residues as indicated in the key (see Experimental Procedures for
details). SUMO conjugation sites and 21 residue sequence windows are shown (right).
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SUMO Targets in Human Induced Pluripotent Stem CellsDuring our analysis, we also found that a large proportion
of modification sites displayed a clear preference for either
SUMO1 or SUMO2, and that this seems to be influenced by
the charge distribution around the acceptor lysine. Specif-
ically, lysines within acidic domains are more likely to be
modified by SUMO2 than SUMO1. While this is by no means
a strict rule, these data suggest that site-level SUMO paralog
selection is at least in part defined by the electrostatic envi-
ronment of the acceptor lysine. Intriguingly, structures of
Ubc9 in complex with either SUMO1 or SUMO2 (51) show
significant charge deviation between the two paralogues
close to the active site of the E2 enzyme (supplemental
Fig. S10), potentially implicating the SUMO molecule itself
in site selection. It is important to note, however, that in spite
of the clear variety of site-level SUMO paralogue preference,
most proteins display little overall SUMO preference when
considering the total cellular pool together, meaning exam-
ples of entirely SUMO1 or SUMO2/3 modified proteins are
probably rare. A notable exception is RanGAP1, which dis-
plays a very strong SUMO1 preference. This is a conse-
quence of the SUMO1 modified form being resistant to
SUMO protease mediated removal, whereas the SUMO2
modified form is susceptible to SUMO protease cleavage
(52). Understanding the differences between SUMO1 and
SUMO2/3 in terms of site selectivity and downstream func-
tional outcomes will likely be critical in gaining a full under-
standing of the role of SUMOylation in all higher eukaryotic
cell types.DATA AVAILABILITY
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